Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
73.35
-0.55 (-0.74%)
4:51:38 PM EDT: $73.33 -0.02 (-0.02%)
Products, Regulatory

Health Canada Approves Keytruda In Combination With Chemotherapy For Treatment Of Certain Type Of Breast Cancer

Published: 11/23/2021 19:10 GMT
Merck & Co Inc (MRK) - Health Canada Approves Keytruda® (pembrolizumab) in Combination With Chemotherapy for the Treatment of Locally Recurrent Unresectable Or Metastatic Triple-negative Breast Cancer Whose Tumors Express Pd-l1 (cps ≥10).
Merck Canada - Conditional Approval Based on Data From Phase 3 Keynote-355 Trial; Introduces First Breast Cancer Indication for Keytruda.